Data Center Construction

Business

MaxLinear Declares 2025 an 'Inflection Year' as Infrastructure and Optical Tech Drive Record Growth

Chip designer MaxLinear capped off a transformative 2025 with a strong fourth quarter, reporting 30% full-year revenue growth and positive cash flow ahead of schedule. CEO Kishore Seendripu pointed to surging demand in data center optical interconnects and wireless infrastructure as key catalysts, positioning the company for even faster growth in 2026.

Jan 30, 2026

Business

AI Demand Fuels SanDisk's Record Quarter, Signals Structural Shift for NAND Industry

SanDisk's Q2 2026 earnings reveal a 31% sequential revenue surge to $3 billion, driven by AI infrastructure build-out. The company highlights a fundamental industry shift towards long-term agreements as data center demand, now the largest NAND market, reshapes commercial dynamics.

Jan 30, 2026

Business

MARA Secures French Nod for Exaion Acquisition, Gaining a Regulated Foothold in Europe's Digital Infrastructure

French regulators have greenlit MARA Holdings' takeover of EDF's data center unit Exaion, imposing strict conditions on energy use and data protection. The deal marks a significant, albeit tightly supervised, expansion of the bitcoin miner's European ambitions into high-performance computing.

Jan 30, 2026

Business

Digital Realty Expands Southeast Asia Footprint, Inks Major Supply Deal to Fuel AI Infrastructure Push

Digital Realty Trust makes a strategic entry into Malaysia with the acquisition of the TelcoHub 1 data center and secures a critical $373 million supply agreement with Schneider Electric, positioning itself to capture surging demand for AI-ready infrastructure in the region.

Jan 30, 2026

Business

Fact Check: Trump's Tariff Triumph Narrative Collides With Economic Data

An analysis of President Trump's recent op-ed claims reveals significant discrepancies between his portrayal of tariff success and official trade figures, price impact studies, and the nuanced reality of their implementation.

Feb 2, 2026

Business

Lexeo Therapeutics Faces Market Skepticism Despite Positive PKP2 Gene Therapy Data

H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.

Feb 2, 2026

Business

Markets Edge Lower Ahead of Key Labor Data, Earnings Deluge

U.S. stock futures pointed to a lower open Monday as investors braced for a flood of corporate earnings and crucial labor market reports that could sway Federal Reserve policy expectations.

Feb 2, 2026

World

Aid Groups Draw 'Red Line' at Israeli Data Demands, Vow to Stay in Gaza Despite MSF Ban

A coalition of major international NGOs is refusing to comply with Israeli orders to hand over detailed staff information, calling it a safety risk and an obstruction of aid, as tensions escalate following the expulsion of Médecins Sans Frontières.

Feb 2, 2026

Business

Bitcoin's Fate Hinges on U.S. Labor Data and MicroStrategy Earnings This Week

As Bitcoin grapples with volatility below $80,000, a packed U.S. economic calendar—featuring key jobs reports and MicroStrategy's Q4 earnings—is poised to dictate the cryptocurrency's near-term trajectory by shaping Federal Reserve policy expectations.

Feb 2, 2026

World

From Doubt to Data: How Western Narratives Initially Undermined Gaza's Death Toll

As Israel now acknowledges over 70,000 killed in Gaza, rights advocates argue that early Western political and media skepticism dehumanized Palestinians and delayed a full reckoning with the war's human cost.

Feb 2, 2026

Business

Sarepta's Gene Therapy Shows Sustained Slowing of DMD Progression in Landmark Three-Year Data

New long-term results from the pivotal EMBARK trial indicate ELEVIDYS, Sarepta's gene therapy, continues to alter the disease trajectory for boys with Duchenne muscular dystrophy, with no new safety concerns emerging over three years.

Jan 31, 2026

Business

Heidelberg Materials Gains Momentum as Investors Bet on Green Cement Boom

Heidelberg Materials (XTRA:HEI) is attracting renewed investor interest, fueled by accelerating global demand for sustainable construction materials. The company's strategic positioning in low-carbon cement and aggregates coincides with strong shareholder returns, raising questions about its current valuation in a rapidly evolving market.

Jan 31, 2026

Business

Palantir's AI Ambition: Can the Data Analytics Powerhouse Sustain Its Meteoric Rise?

From a $10 direct listing to a $150 S&P 500 constituent, Palantir's journey has been fueled by the AI boom. As government and commercial demand surge, analysts project staggering growth. But with sky-high valuations, the path forward requires navigating lofty expectations.

Jan 30, 2026

World

MSF Refuses Israeli Demand for Staff Data, Citing Safety Risks in Gaza

Doctors Without Borders (MSF) has definitively rejected an Israeli order to hand over sensitive staff information, following months of failed negotiations. The move comes amid a wider crackdown on aid groups and a devastating toll on healthcare workers in the conflict.

Jan 30, 2026

Business

Slovenia Taps Planet Labs for Satellite Data, as Market Weighs High-Flying Valuation

Planet Labs secures a strategic enterprise agreement with the Slovenian government, expanding its public sector footprint with applications in agriculture, urban development, and disaster preparedness. The deal comes as investors scrutinize the company's premium market valuation amidst growing competition in the Earth observation sector.

Jan 30, 2026

Business

Equifax Bets on AI and Verified Data to Deepen Its Moat, But Can It Justify the Premium?

Equifax is expanding beyond traditional credit reporting with a new suite of AI-powered fraud detection and income verification tools. While this strategic push aims to embed the company deeper into the lending ecosystem, analysts remain divided on whether it's enough to support its current valuation amid high debt and execution risks.

Jan 30, 2026

Business

Mineralys Therapeutics Submits New Drug Application for Hypertension Treatment Lorundrostat, Backed by Strong Clinical Data

Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.

Jan 30, 2026

Business

AI Data Surge Fuels Western Digital's Strong Q2, Drives High-Capacity Storage Demand

Western Digital's fiscal Q2 2026 results showcase robust growth, with revenue climbing 25% year-over-year to $3.0 billion. The company credits accelerating AI adoption for driving demand for its high-capacity nearline hard drives and advanced technologies like HAMR and UltraSMR.

Jan 30, 2026

Business

Piper Sandler Trims Price Target for Black Diamond Therapeutics Amid Model Review, Despite Recent Clinical Wins

Analyst Piper Sandler has lowered its price target on Black Diamond Therapeutics (BDTX) while maintaining an Overweight rating, following a broad review of its biotech coverage. The adjustment comes even as the company recently reported encouraging Phase 2 data for its lead oncology drug candidate.

Feb 2, 2026

Business

Saint-Gobain Shares Dip: A Buying Opportunity or a Sign of Deeper Headwinds?

After a recent pullback, shares of French construction materials giant Saint-Gobain are trading at a notable discount to analyst targets. While long-term performance remains robust, investors are weighing near-term risks against potential value.

Feb 2, 2026